BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
18
Data completeness
4/8 — Partial
Priority Review
VEOPOZ (pozelimab) by Regeneron is complement inhibitors [moa]. Approved for complement inhibitor [epc]. First approved in 2023.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEOPOZ (pozelimab) is a monoclonal antibody complement inhibitor approved by the FDA in August 2023. It works by blocking complement cascade activation to treat rare complement-mediated diseases. The drug represents Regeneron's entry into the growing complement inhibitor market.
Growth
Early-stage growth product with competitive pressure at 30%, offering opportunities in market expansion and team building within a niche therapeutic area.
Mechanism of Action
Complement Inhibitors
Pharmacologic Class:
Complement Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
Started Jun 2026
35 enrolled
Paroxysmal Nocturnal Hemoglobinuria
A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease
Started Mar 2026
5 enrolled
CHAPLE Disease
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Started Jan 2026
54 enrolled
Geographic Atrophy (GA)
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Started Oct 2024
975 enrolled
Age-related Macular Degeneration (AMD)Geographic Atrophy (GA)
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
Started Aug 2024
10 enrolled
Sporadic Inclusion Body Myositis (sIBM)Idiopathic Inflammatory Myopathies
Worked on VEOPOZ at Regeneron? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.